MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice

Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small‐cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET‐tyrosine kinase inhibitors (TKIs), underlying the need to understand the...

詳細記述

書誌詳細

主要な著者:	Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie‐José Truong, Valérie Grégoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean‐Pascal Meneboo, Shéhérazade Sebda, Katia Bouchekioua‐Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie‐Christine Copin, David Tulasne, Alexis B. Cortot, Stéphanie Kermorgant, Zoulika Kherrouche
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2023-11-01
シリーズ:	Molecular Oncology
主題:	hepatocyte growth factor lung cancer preclinical models targeted therapies transcriptomic tyrosine kinase receptor
オンライン･アクセス:	https://doi.org/10.1002/1878-0261.13397
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!